Equities Analysts Offer Predictions for VVOS Q3 Earnings

Vivos Therapeutics, Inc. (NASDAQ:VVOS) – HC Wainwright issued their Q3 2025 earnings estimates for Vivos Therapeutics in a report released on Monday, November 17th. HC Wainwright analyst Y. Chen anticipates that the company will post earnings per share of ($0.55) for the quarter. HC Wainwright currently has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for Vivos Therapeutics’ current full-year earnings is ($1.79) per share. HC Wainwright also issued estimates for Vivos Therapeutics’ Q4 2025 earnings at ($0.46) EPS, FY2025 earnings at ($2.00) EPS, Q1 2026 earnings at ($0.38) EPS, Q2 2026 earnings at ($0.32) EPS, Q3 2026 earnings at ($0.28) EPS, Q4 2026 earnings at ($0.24) EPS and FY2026 earnings at ($1.19) EPS.

Other analysts also recently issued reports about the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Vivos Therapeutics in a report on Wednesday, October 8th. Zacks Research lowered shares of Vivos Therapeutics from a “hold” rating to a “strong sell” rating in a report on Friday, October 31st. Wall Street Zen downgraded Vivos Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, August 10th. Finally, Ascendiant Capital Markets boosted their price objective on Vivos Therapeutics from $6.20 to $6.50 and gave the company a “buy” rating in a report on Tuesday, September 9th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, Vivos Therapeutics presently has an average rating of “Hold” and an average target price of $5.25.

Vivos Therapeutics Stock Performance

Shares of VVOS stock opened at $2.47 on Wednesday. The business has a fifty day moving average of $2.97 and a 200 day moving average of $3.52. Vivos Therapeutics has a 1 year low of $1.98 and a 1 year high of $7.95. The company has a debt-to-equity ratio of 1.69, a current ratio of 1.05 and a quick ratio of 1.05. The firm has a market capitalization of $18.54 million, a price-to-earnings ratio of -1.47 and a beta of 6.88.

Vivos Therapeutics (NASDAQ:VVOS) last announced its quarterly earnings data on Tuesday, August 19th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.16). Vivos Therapeutics had a negative net margin of 99.49% and a negative return on equity of 232.76%. The company had revenue of $3.82 million for the quarter, compared to analysts’ expectations of $3.37 million.

Institutional Trading of Vivos Therapeutics

Several large investors have recently made changes to their positions in VVOS. Connective Capital Management LLC purchased a new stake in shares of Vivos Therapeutics during the third quarter worth $620,000. B. Riley Wealth Advisors Inc. acquired a new position in Vivos Therapeutics during the second quarter worth about $220,000. Finally, XTX Topco Ltd purchased a new stake in Vivos Therapeutics during the 2nd quarter valued at about $65,000. 26.35% of the stock is currently owned by hedge funds and other institutional investors.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.